Starting soon
Phase 2/3
Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer
Condition(s) studied
Pancreatic Cancer
Investigational drug(s) / intervention(s)
Nimotuzumab: Patients will receive Nimotuzumab 400 mg weekly or Nimotuzumab 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
GX: Patients will receive GX as adjuvant therapy for 6 months. Gemcitabine will be delivered as a 1000 mg/m² intravenous infusion administered on Day 1 and 8 of a 21-day cycle. Capecitabine 2000mg/m²/day will be administered orally for 14 days followed by 7 days' rest.
Placebo: Patients will receive placebo 400 mg weekly or placebo 600 mg on Day 1 and 8 of a 21-day cycle, up to 6 months.
Study summary
This is a prospective, multicenter, randomized, double-blind, placebo-controlled study. The main purpose of the study is to evaluate the clinical efficacy and safety of Nimotuzumab combined with GX for postoperative adjuvant treatment of pancreatic cancer.
Eligibility
Inclusion Criteria:
* 1\. Able and willing to provide a written informed consent.
* 2\. Age 18-75 years old, gender unlimited;
* 3\. Histologically or cytologically confirmed resected pancreatic ductal adenocarcinoma (PDAC), resectable evaluation is based on criteria of NCCN guidelines, no evidence of distant metastasis as demonstrated by imaging;
* 4\. Postoperative pathology suggested R0/R1 resection;
* 5\. Adequate organ and bone marrow function, defined as follows: absolute neutrophil count (ANC)≥1.5×10\^9/L; platelets≥100×10\^9/L; hemoglobin≥9.0 g/dL; serum total bilirubin (TBIL)≤1.5×ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times the upper limit of normal (ULN); serum creatinine≤1.5×ULN or estimated creatinine clearance \> 60 mL/min;
* 6\. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
* 7\. Postoperative survival is expected to be ≥3 months;
* 8\. Fertile subjects are willing to take contraceptive measures during the study period.
Exclusion Criteria:
* 1\. Prior neo-adjuvant treatment, radiation therapy, or systemic therapy for pancreatic adenocarcinoma;
* 2\. Accompanied by other serious diseases, including but not limited to: active infections; unmanageable diabetes mellitus and uncontrolled hypertension (SBP\>160mmHg or DBP\>100mmHg); compensatory heart failure (NYHA grade III and IV), unstable angina or poorly controlled arrhythmias within 3 months prior to randomization; presence of uncontrolled pleural effusion, pericardial effusion, or ascites requiring drainage; severe portal hypertension; gastric outlet obstruction; Respiratory insufficiency and Severe lung disease; Central Nervous System Disease or mental illness;
* 3\. History of other malignancies (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
* 4\. bleeding or clotting disorder;
* 5.Postoperative complications such as bleeding, pancreatic fistula, gastric obstruction, abdominal infection, and biliary fistula, which made the patient unable to receive adjuvant therapy within 12 weeks after surgery;
* 6\. Known allergy to prescription or any component of the prescription used in this study;
* 7\. Factors that significantly affect oral drug absorption, such as dysphagia, chronic diarrhea, gastrointestinal obstruction, etc;
* 8\. Known HIV, or syphilis infection, or active hepatitis (hepatitis B, hepatitis C);
* 9.Other reasons that are not suitable to participate in this study according to the researcher's judgment
Primary outcome measure(s)
- relapse-free survival (RFS) — Up to 24 months
The time from the date of surgery to the disease recurrence or death, whichever is earlier.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| Tianjin Medical University Cancer Institute and Hospital |
Tianjin |
China |
|
More Tianjin Medical University Cancer Institute and Hospital trials in China
Other trials for the same condition
